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Introduction

D
iscovered in the early 1990s, HIV-1 group O (outlier, HIV-1/O) infections have been mostly reported from West-Central Africa and have not spread significantly beyond Cameroon, Nigeria, Gabon, and Equatorial Guinea. 1 In Cameroon, HIV-1/O infections have been well documented and are found in around 1% of people living with HIV/AIDS. 2 By contrast, little is known about HIV-1/O infections in neighboring countries such as Gabon. In a previous work published in 1997 by Peeters et al., two cases of HIV-1/O infections were diagnosed among 213 tested Gabonese HIVpositive sera, yielding a prevalence rate of 0.9%. 3 To date, the natural history of HIV-1/O infections as well as the intragroup genetic diversity of HIV-1/O strains circulating in Gabon are poorly documented. As recommended by the World Health Organization (WHO) in resource-limited countries, the scaling-up of first-line antiretroviral (ARV) regimens uses systematically nonnucleoside reverse transcriptase inhibitors (NNRTIs). The efficiency of this Public Health approach was recently described in Gabon. 4 Unfortunately, this strategy is not fully satisfactory in WestCentral African countries since most of HIV-1/O isolates are naturally resistant to NNRTIs due to the presence of the Y181C mutation. 5, 6 The main goals of the present study conducted in Gabon were to determine the prevalence rate of HIV-1/O infections in this country by using an in-house serotyping assay and to characterize the genetic diversity of HIV-1/O strains and implications on ARV drug resistance. 
Materials and Methods
Study patients
This study was conducted between January 2010 and December 2011 at the retrovirology laboratory of the Centre International de Recherches Médicales de Franceville (CIRMF, Gabon). Whole blood specimens were collected in EDTA tubes from three Gabonese HIV care centers providing ART and located in Franceville (FCV) (a town of *75,000 inhabitants in the Haut-Ogooué province), Koulamoutou (KMO) (a town of *15,000 inhabitants in the Ogooué-Lolo province), and Libreville (LBV) (the capital city of Gabon in the Estuaire province). The study was approved by the ethical biomedical research committee of Franceville (No. 023/2010/MESRS/ CERB). 4 Serotyping and molecular HIV-1/O assays For HIV-1/O diagnosis, we implemented a variant serological strategy by using an in-house serotyping env gp120 V3 loop region immunoassay as described elsewhere. 7 For this purpose, five V3 peptide antigens were used for specific identification of HIV-1 groups M, N, O, and P, and HIV-2 infections. Plasma HIV-1/O RNA levels were determined using the Abbott RealTime HIV-1 assay (Abbott, Des Plaines, IL) according to the manufacturer's instructions. We also used two HIV-1/O consensual env primers V70.1_2s (ACACATGGYATYAAGCCAACAGTAAG) and V70.5_2as (GTTCTCCATATATC TYTCATATCYCCCCCT). Using these primers, we amplified three overlapping fragments covering the whole genome by nested polymerase chain reaction (PCR) as follows: a 4-kb gag-pol fragment using O-gagF1/O-polR1 for the first round following by O-gagF2/O-polR2 for the second round; a 3-kb pol-env fragment using O-polF1/O-envR1 for the first round following by O-polF2/V70.5_2as for the second round; and a 4.5-kb env-gag (circular DNA) fragment using O-envF1/O-gagR1 for the first round following by V70.1_2s / O-gagR2 for the second round.
Full-length HIV-1/O genomes
All PCR amplifications were performed using the Long Expand PCR kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer's instructions. Each amplification reaction included a manual hot-start followed by 35 to 40 cycles. Annealing temperatures were set according to the primer melting temperatures. Extension times varied depending on the size of the expected fragment and were typically set at 1 min/kb. PCR products were purified on 1% agarose gel with a QBIOgene GENECLEAN Turbo kit (MP Biochemicals). Direct sequencing of both strands using the Big Dye terminator technology [ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit with AmpliTaq FS DNA polymerase (PE Biosystems, Warrington, England)] was performed on an ABI 3130xl Genetic Analyser. Sequences were then assembled using the software package Lasergene (DNASTAR, Inc., MAD). Overlapping sequence fragments were assembled using DNAstar package (Lasergene).
Newly derived HIV-1 group O Gag, Pol, and Env amino acid and nucleic acid sequences were aligned with 21 available and independent full length HIV-1/O sequences from the GenBank by using MEGA4 with minor manual adjustments if necessary. 8 Appropriate models of evolution were selected for each data set using Topali v2.5 software and maximum likelihood phylogenies were reconstructed using PhyML. 9, 10 To define newly derived HIV-1/O clades, we used the classification proposed by Yamaguchi et al.
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ARV resistance genotypic patterns ARV drug resistance mutations were identified and interpreted using the ANRS algorithm (version 21, October 2011) (www.hivfrenchresistance.org). Mutations were also studied using the Stanford HIVdb genotypic resistance algorithm and then coded as major resistant mutations using the International AIDS Society (IAS) list from January 2012 (http:// hivdb.stanford.edu). For the analysis of the gag and gag-pol genes cleavage sites, we used 21 available HIV-1/O fulllength sequences from the GenBank and compared them with the HIV-1 group M reference strain HIV HXB2 .
Results
Prevalence rate of HIV-1/O infection
A total of 1,176 specimens were serotyped (FCV, n = 544; LBV, n = 457; and KMO, n = 175). Four subjects (one from FCV and three from LBV) infected with an HIV-1/O strain were identified, yielding an overall prevalence of HIV-1/O infections in Gabonese HIV-1-infected subjects of 0.34% (95% confidence interval, 0.11-0.82). Among these four specimens, optical densities (ODs) found for the O peptide oscillated between 0.386 and 1.505 whereas ODs were strictly negative (< 0.1) for the HIV-1 M, N, and P as well as HIV-2 peptides. No dual O + M specimen was observed. A vast majority (1,118/1,176; 95.1%) of patients were infected with HIV-1 strains belonging to group M whereas 51 (4.3%) subjects showed negative or indeterminate results. HIV-2 infection was found for three (0.26%) individuals, including two with a dual HIV-1/HIV-2 reactivity. No case of HIV-1 group N or P infection was found.
Epidemiological, clinical, and immunovirological characteristics of subjects infected with HIV-1/O strains
The main features of the four HIV-1/O-infected patients are presented in Table 1 . Three were men. All subjects were aged > 40 years. Two individuals were born at Oyem, a city located in North Gabon. At the time of HIV-1/O diagnosis, three patients progressed to CDC stage C. One subject (LBV#1744) who was untreated with ARVs died 2 months 
FIG. 1.
Phylogenetic relationships of two newly derived viruses (10Gab1190 and 11Gab6352) to the previously described strains in gag, pol, and env genes, as inferred by the maximum likelihood method from nucleotide sequence alignments (see Materials and Methods for further details). The classification used was proposed by Yamaguchi et al. 8 Bootstrap values ‡ 80% are indicated by an asterisk.
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Pol, and Env amino acids sequences, the tree topologies were different (data not shown). In both nucleic and amino acids analyses, bootstrap values were nonsignificant, making the classification of this strain quite difficult. Table 2 , at positions associated with resistance to NRTIs, the two strains HIV-1/O 10Gab#1190 and 11Gab #6352 harbored the uncommon mutations V118C and L210Y. The T69N mutation was observed for strain HIV-1/O 10Gab#1190 only. The M41L, M184V, and T215Y DRMs were found in the 11Gab#6352, making this strain resistant (intermediate or high-level) to all NRTIs according to the Stanford algorithm. According to the ANRS algorithm, this strain was resistant (intermediate or high-level) to zidovudine (AZT), stavudine (d4T), lamivudine (3TC), emtricitabine (FTC), and abacavir (ABC) but remained susceptible to didanosine (ddI) and tenofovir (TDF). When considering positions associated with resistance to NNRTIs (Table 2) , the two HIV-1/O samples harbored the Y181C mutation making them resistant to firstgeneration NNRTIs. For etravirine, they were susceptible according to the ANRS algorithm but intermediate using the Stanford interpretation. For rilpivirine, they were intermediate with both algorithms. In the protease gene, multiple minor resistance mutations were found for both strains (Table 3) . They remained susceptible to atazanavir, darunavir, fosamprenavir, indinavir, and lopinavir, whatever the algorithm used. They showed discrepancies between the two algorithms for nelfinavir, saquinavir, and tipranavir. A high natural polymorphism in the gag gene cleavage sites was obtained for both strains, mostly in the p1/p6, TFP/p6 pol , and p6 pol sites (Fig. 2) . For the two strains, no major resistance mutation (such as E157Q) was detected in the integrase gene, indicating a conserved susceptibility to integrase inhibitors [(INI) such as elvitegravir (EVG), raltegravir (RAL), and dolutegravir (DTG)] with both ANRS and Stanford algorithms. The two samples carried the N42D mutation within the HR1 domain of gp41, conferring a resistance to enfuvirtide (ENF) according to the ANRS algorithm.
Antiretroviral drug resistance results
As shown in
Discussion
It remains unknown why HIV-1/O variants constitute a low-level background in their contribution to the global HIV/ AIDS pandemic, contrary to the dramatic increase of HIV-1M strains. In our study, we confirmed a low HIV-1 group O prevalence in Gabon, accounting for only 0.3% (95% CI, 0.1-0.8) of HIV-1 infections diagnosed in 2010-2011. It is lower than the 0.9% (95% CI 0.2-3.0) rate previously reported for this country in 1997. 3 Given that the p value between the two prevalence rates was not statistically significant (v 2 test, p = 0.22), we were not able to draw solid conclusions about the 
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trend (declining or stable or increasing) of HIV-1/O prevalence over time in Gabon. Even if two individuals were born in Oyem, a Gabonese city located in the Woleu-Ntem province, it was difficult to demonstrate higher prevalence rates of HIV-1/O infections in North Gabon compared to other Gabonese areas. North Gabon is just neighboring to Cameroon, which is known to be the epicenter of HIV-1/O infections. [11] [12] [13] In our study, full-length genome analyses revealed that one strain (10Gab1190) clustered with the ANT70 archetype HIV-1/O strain along its whole genome. By contrast, the 11Gab6352 strain remained unclassifiable. Given that only 21 independent HIV-1/O full-length genomes are available in the HIV sequence database (http://www.hiv.lanl.gov/cgibin/NEWALIGN/ align.cgi), the classification of HIV-1/O strains into distinct subtypes remains difficult to perform.
Little is known about the efficacy of antiretroviral drugs on HIV-1/O strains, with sometimes a poor agreement between the genotypic resistance testing results designed for HIV-1
FIG. 2.
Gag and gag-pol cleavage site substitutions in two protease inhibitor-naive subjects infected with HIV-1/ O strains in Gabon. Frequencies (horizontal bars) of each substitution were obtained from 21 independent HIV-1/O sequences (see Materials and Methods).
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group M and in vivo virological responses. 14, 15 For the two HIV-1/O strains well-characterized in our study, and as previously described by other teams, we found a wide range of natural polymorphism in the protease, gp41, gag, and gagpol regions such as (1) about 15 natural sequence polymorphisms in the protease (that may contribute to a more rapid virological failure to PIs), 16 (2) the signature N42D mutation in the gp41 (whose impact on ENF needs to be further assessed in vivo), 17 (3) and a high polymorphism in some gag and gag-pol cleavage sites (which may be associated with a higher risk of virological failure on PI-based monotherapy). 18 Conversely, no polymorphism was observed in the integrase gene, as reported by others. 19 For the reverse transcriptase gene, we were not able to determine if mutations were due to ARV pressure or were naturally present before ARV treatment. The presence of the Y181C mutation made the two strains resistant to first-generation NNRTIs, whereas a few minor mutations (A98G, V179E) led to possible resistance to newly developed NNRTIs such as etravirine and rilpivirine. In addition, the 11Gab#6352 strain harbored M184V and some TAM-1 mutations (M41L, T215Y) leading to resistance to all NRTIs using the Stanford algorithm. As a consequence, this viral strain was predicted to be resistant to all three drugs constituting the ARV regimen. Patient LBV#6352 was thus clearly infected with a multidrug-class-resistant HIV-1/O strain and is still waiting for a salvage ARV regimen such as TDF + IP/r (such as LPV/r) + INI (such as EVG or RAL) whose access is quite difficult in Gabon. The efficacy of an INI-based regimen has been recently reported for one patient in Cameroon. 20 In conclusion, individuals infected with HIV-1/O variants are rare in Gabon. However, they should be diagnosed earlier and accurately followed-up in order to switch without delay from inefficient NNRTI-based regimens to appropriate ARV regimens including PIs and/or INIs.
